As shelf-stable microarray patch (MAP) platforms move through development and clinical work, a ‘packaging first’ mentality is needed for industry-wide adoption.

SK bioscience announced that, together with IDT Biologika (IDT) and Australian biotechnology company Vaxxas, it has been ...

The panel ensures compatibility with our previous autosomal Family Finder tests plus all the autosomal transfers we ...

DNA microarray technology is a powerful tool to investigate the expression pattern of a high number of genes in parallel. A major experimental challenge of this emerging technology is establishing the ...

We reviewed the options for the manufacture and use of DNA microarrays in the original Chipping Forecast 1 in 1999. Since then, the number of companies that produce microarrays equipment and reagents ...

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 3 of Bionano Symposium 2026, entitled OGM Making its Mark in Constitutional Genetic Disorders. Presentations highlighted how ...

Vaxxas has been awarded a tender by the European Health and Digital Executive Agency to help develop next-generation ...

SK Bioscience said Thursday it has secured its first European Union-backed vaccine development project alongside German subsidiary IDT Biologika, marking a key ...

SK bioscience, IDT Biologika, and Vaxxas will collaborate on a next-generation influenza vaccine development initiative.

Explore essential statistical strategies for accurate protein quantification and differential expression analysis.

A Brisbane-based biotechnology company behind a needle-free vaccine patch has warned it could take its technology offshore after securing a multimillion-dollar funding boost from European authorities, ...